Global Blood Therapeutics - Stock Price History | GBT

Historical daily share price chart and data for Global Blood Therapeutics since 2021 adjusted for splits. The latest closing stock price for Global Blood Therapeutics as of September 27, 2021 is 26.22.
  • The all-time high Global Blood Therapeutics stock closing price was 87.20 on January 16, 2020.
  • The Global Blood Therapeutics 52-week high stock price is 64.49, which is 146% above the current share price.
  • The Global Blood Therapeutics 52-week low stock price is 25.35, which is 3.3% below the current share price.
  • The average Global Blood Therapeutics stock price for the last 52 weeks is 41.11.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Global Blood Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 62.0432 78.5700 87.2000 37.6500 43.3100 -45.52%
2019 54.5470 41.1300 81.8600 39.9900 79.4900 93.64%
2018 45.6882 41.6000 65.9000 31.5400 41.0500 4.32%
2017 30.1224 14.3000 45.7000 14.3000 39.3500 172.32%
2016 18.6577 29.2100 29.2100 12.9500 14.4500 -55.30%
2015 44.6724 43.1100 54.6600 30.3800 32.3300 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.636B $0.124B
Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29